Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions

BRAF V600 Colorectal Cancer

Interventions

DRUG

Iparomlimab and Tuvonralimab

3mg/kg，ivdrip

DRUG

Bevacizumab

5mg/kg，ivdrip

DRUG

5-Fluorouracil

400mg/m2 iv followed by 2.4g/m2 civ 48h

DRUG

Irinotecan (drug)

180mg/m2

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT07150247 - Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter